111 related articles for article (PubMed ID: 35981360)
1. [The Effect of KRAS on Proliferation and Apoptosis of T-ALL Cell Lines].
Liu ZY; Shu Y; Fu G; Su HY; Zhu D; Zeng LM; Ma DY; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1040-1048. PubMed ID: 35981360
[TBL] [Abstract][Full Text] [Related]
2. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
[TBL] [Abstract][Full Text] [Related]
3. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
Wen Z; Yun G; Hebert A; Kong G; Ranheim EA; Finn R; Rajagoplan A; Li S; Zhou Y; Yu M; Damnernsawad A; Roose JP; Coon JJ; Wen R; Wang D; Zhang J
Blood; 2021 Jun; 137(23):3259-3271. PubMed ID: 33512434
[TBL] [Abstract][Full Text] [Related]
4. Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
Staffas A; Karlsson C; Persson M; Palmqvist L; Bergo MO
Leukemia; 2015 May; 29(5):1032-40. PubMed ID: 25371176
[TBL] [Abstract][Full Text] [Related]
5. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
7. A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA; Han JJW; Lee YH; Lee CS; Luo J
Cancer Res; 2023 Sep; 83(17):2816-2823. PubMed ID: 37339170
[TBL] [Abstract][Full Text] [Related]
8. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
9. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
10. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
Dail M; Li Q; McDaniel A; Wong J; Akagi K; Huang B; Kang HC; Kogan SC; Shokat K; Wolff L; Braun BS; Shannon K
Proc Natl Acad Sci U S A; 2010 Mar; 107(11):5106-11. PubMed ID: 20194733
[TBL] [Abstract][Full Text] [Related]
11. Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.
Figueiredo ML; Stein TJ; Jochem A; Sandgren EP
Liver Int; 2012 Apr; 32(4):582-91. PubMed ID: 22221894
[TBL] [Abstract][Full Text] [Related]
12. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
13. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
14. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis.
Zhang Y; Liu JL; Wang J
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3085-3096. PubMed ID: 32271426
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
[TBL] [Abstract][Full Text] [Related]
16. Involvement of KRAS G12A mutation in the IL-2-independent growth of a human T-LGL leukemia cell line, PLT-2.
Mizutani N; Ito H; Hagiwara K; Kobayashi M; Hoshikawa A; Nishida Y; Takagi A; Kojima T; Suzuki M; Osawa Y; Ohnishi K; Daibata M; Murate T
Nagoya J Med Sci; 2012 Aug; 74(3-4):261-71. PubMed ID: 23092099
[TBL] [Abstract][Full Text] [Related]
17. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
Maitra R; Seetharam R; Tesfa L; Augustine TA; Klampfer L; Coffey MC; Mariadason JM; Goel S
Oncotarget; 2014 May; 5(9):2807-19. PubMed ID: 24798549
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
[TBL] [Abstract][Full Text] [Related]
20. [Potential Oncogenic Role of Genes in PLC Family on T-ALL Cell Lines by Suppression of Apoptosis].
Zeng LM; Shu Y; Zhu D; Ma DY; Filippus IT; Zhang HY; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(4):931-938. PubMed ID: 37551458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]